Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599783 | 0.89 | MEN1 (0.47) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL3601902 | 0.87 | ALDH1A1 (0.47) | MEN1KMT2AMAPTNPSR1NPC1 | |
| SCHEMBL3605966 | 0.86 | MEN1 (0.48) | MEN1KMT2AF13A1TGM2TGM1 | |
| SCHEMBL3603606 | 0.85 | NPC1 (0.61) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3602857 | 0.84 | MEN1 (0.48) | MEN1KMT2AF13A1TGM2TGM1 | |
| SCHEMBL3605934 | 0.84 | NAMPT (0.48) | MEN1KMT2AMAPT | |
| SCHEMBL3592513 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2AMAPTNPSR1RAB9A | |
| SCHEMBL3600141 | 0.84 | MEN1 (0.42) | MEN1KMT2AF13A1TGM2TGM1 | |
| SCHEMBL3607841 | 0.84 | NPC1 (0.46) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3601798 | 0.83 | CCR3 (0.52) | MEN1KMT2AMAPTNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | MEN1 1716/4885KMT2A 967/4885F13A1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.